泰恩康：发布2026年员工持股计划 设定三年业绩考核目标

Core Viewpoint - The company has announced an employee stock ownership plan (ESOP) for 2026, aiming to incentivize up to 145 individuals, including directors and key employees, with a total funding cap of 33.608 million yuan [1] Group 1: Employee Stock Ownership Plan - The ESOP will be funded through employees' legal salaries and self-raised funds, with no financial assistance or loan guarantees provided by the company [1] - The repurchase price for the shares is set at 16.93 yuan per share, with a maximum of 1.9851 million shares to be held, representing approximately 0.47% of the total share capital [1] - Performance targets for the years 2026 to 2028 have been established, with revenue and profit goals progressively increasing each year [1] Group 2: Performance Assessment and Goals - For 2026, the revenue target is set at 1 billion yuan, with a trigger value of 900 million yuan; the profit target is 300 million yuan, with a trigger value of 270 million yuan [1] - The revenue target for 2027 increases to 1.5 billion yuan (trigger value: 1.35 billion yuan), and the profit target rises to 500 million yuan (trigger value: 450 million yuan) [1] - By 2028, the revenue target reaches 2 billion yuan (trigger value: 1.8 billion yuan), and the profit target is set at 800 million yuan (trigger value: 720 million yuan) [1] Group 3: Unlocking Rules and Strategic Goals - If either revenue or profit meets the target, the unlocking ratio is 100%; if both meet the trigger values but not the targets, the unlocking ratio is 90% [2] - The ESOP aims to establish a profit-sharing mechanism between employees and the company, enhancing team stability and competitiveness to support long-term strategic goals [2] Group 4: Product Pipeline and Market Position - The company has received approval for a Phase II clinical trial of its core product, CKBA cream, targeting pediatric vitiligo, with patient enrollment expected to start in Q1 2026 [2] - The company anticipates approvals for its generic drugs, including compound sodium sulfate tablets and a unique gastrointestinal product, in the first half of 2026, with another eye medication expected in the second half [2] - The company forecasts continued growth in its sexual health segment, driven by brand promotion and the launch of new products [3]